Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

NCT05879432 is registered in ClinicalTrials.gov with Arch Biopartners Inc. as lead sponsor.

NCT NCT05879432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Lead sponsor
Arch Biopartners Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
March 8, 2024
Completion date
August 31, 2027
Enrollment
240 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, cardiac surgery